Eli Lilly announced impressive Q1 2024 financial results, with revenue surging by 26% YoY and exceeding expectations for earnings per share. The company raised its full-year 2024 revenue guidance ...
Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.
Glencar has taken over the construction of a life sciences building near Cambridge from collapsed contractor Readie. Readie ...
Shares of Eli Lilly (NYSE:LLY) reached new all-time highs this week, driven by the continued share price and fundamental momentum, and by what some would say is the obesity market hype. The former ...
Lilly added a FTD prospect to its pipeline when it bought Prevail Therapeutics for $880 million and has a stake in Arkuda Therapeutics. Eli Lilly QurAlis amyotrophic lateral sclerosis dementia ...
The incident comes after a series of official investigations last year related to the issuance of fake birth certificates at a time when China is trying to boost its birth rate. Cardinal now expects ...
QurAlis granted Lilly an exclusive, worldwide license to develop and commercialize QRL-204. The agreement includes a research and development collaboration to identify and develop additional ...
We recently published a list of Jim Cramer's Top 10 Stock Picks for June. Since Eli Lilly And Co (NYSE:LLY) ranks higher in the list, the stock deserves a deeper look. But first, let's see what ...
, opens new tab weight-loss drug Mounjaro for some patients with obesity and suggested not placing a time limit on the medicine's use as it had for rival Novo Nordisk's (NOVOb.CO) , opens new tab ...
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said. New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast. The FDA approved the pharma ...